TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00975923

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Collaborative Group
Description: In addition to the Tool Kit materials and web site support, facility leaders and managers in this group agreed to participate in a Collaborative to improve critical care. The Collaborative differed from the IHI BTS model in that teams did not come together for face-to-face educational and planning sessions but instead attended web seminars and teleconferences. Between these virtual learning sessions, teams implemented some of the suggested change ideas, measured the results of those changes, and reported back to the larger group. Teams were supported through monthly educational and troubleshooting conference calls, individual coaching by faculty members, and an e-mail listserver designed to stimulate interaction among teams.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Tool Kit
Description: Hospitals received a tool kit:evidence-based guidelines, CLABSI/VAP fact sheets, change ideas,quality improvement and teamwork methods, standardized data collection and charting tools. Periodic reminders of their commitment to the Safe Critical Care Initiative and access to web site containing all of the educational seminars, clinical tools, and quality improvement tools. ICUs in this group were on their own to initiate and implement a local hospital quality improvement initiative preventing CLABSI and VAP.
Study: NCT01307072

Intervention type: PROCEDURE
Intervention: Vitrectomy
Description: Vitrectomy. Diabetic retinopathy

Intervention type: PROCEDURE
Intervention: Vitrectomy
Description: Vitrectomy. Diabetic retinopathy

Intervention type: PROCEDURE
Intervention: Vitrectomy
Description: Vitrectomy. Diabetic retinopathy
Study: NCT02845804

Intervention type: DEVICE
Intervention: Alpine
Study: NCT01887808

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cetaphil DermaControl Oil Control Moisturizer SPF 30
Study: NCT00889434

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: ECGC
Description: 1 cycle will comprise 28 days of continuous daily treatment with EGCG given once/day(total 375 mg) /day in the morning with food followed by a 14 day wash out period without drug.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Tocotrienol
Description: One cycle will comprise 28 days of continuous daily treatment with Tocotrienol given 2 times/6 soft gel capsules (total 600 mg) /day (BID) in the morning and in the evening with food followed by a 14 day wash out period without drug.

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: EGCG + Tocotrienol
Description: combination of both arms 375 mg EGCG + 600mg/day Tocotrienol
Study: NCT02460731

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fresh Frozen Plasma
Description: Fresh Frozen Plasma \[young (\<30 years of age) healthy male donors\] Solution for intravenous infusion
Study: NCT01940588

Intervention type: BEHAVIORAL
Intervention: Neuropsychoanalytic therapy
Description: Psychotherapy, medication management
Study: NCT03325439

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brivaracetam (BRV) intravenous (iv)
Description: Exploratory Cohort:~Subjects will be dosed with BRV (0.5 mg/kg twice daily (bid)) according to the sites standard procedures. Treatment with 1 or more of the following antiepileptic drugs (AEDs): phenobarbital (PB), midazolam (MDZ), phenytoin (PHT), levetiracetam (LEV), or lidocaine (LDC) (first-line, second-line, or subsequent treatment) will continue in parallel with BRV treatment.~Confirmatory Cohort:~For subjects who enter the Confirmatory Cohorts, for the strength of BRV 1 mg/kg bid (2 mg/kg/day) has been determined based on the Pharmacokinetic (PK) findings of the Exploratory Cohort. Based on further monitoring of PK and safety findings dosing may be adjusted as new data are available. Administration of BRV is proposed as approximately 15-minute intravenous (iv) infusions. Treatment with previous antiepileptic drugs is permitted to continue if the subject is on a stable dose from 1 hour prior to initiation of the BRV treatment.
Study: NCT01552434

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valproic Acid
Description: Given PO
Study: NCT03216629

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Saying sorry
Description: The objective of this study is to investigate how empathy expressed in form of saying sorry affect the perception of pain during dressing change?
Study: NCT03325439

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brivaracetam (BRV) oral
Description: Subjects can switch from intravenous (iv) to oral brivaracetam (BRV) at any time during the BRV Extension Period
Study: NCT01925794

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: COBRA PzF
Study: NCT03301714

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Oral Health Education
Description: Group-based oral health education vs Individual-based oral health education using motivational interviewing

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Oral Health Education
Description: Group-based oral health education vs Individual-based oral health education using motivational interviewing
Study: NCT03897621

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic Acid
Description: tranexamic acid will be administered intravenously after induction of anesthesia (a bolus of 10 mg/kg or maximal dose of 1g).
Study: NCT06217679

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control Oral Glucose Tolerance Test
Description: control oral glucose tolerance test

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control Oral Glucose Tolerance Test
Description: control oral glucose tolerance test

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control Oral Glucose Tolerance Test
Description: control oral glucose tolerance test

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control Oral Glucose Tolerance Test
Description: control oral glucose tolerance test

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mixed Exercise
Description: exercise performed in randomized order
Study: NCT03897621

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients in the placebo group will receive normal saline (a bolus of sodium chloride 0.9%, 0.1 mL/kg or maximal dose of 10 mL).
Study: NCT01460472

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Racotumomab
Description: Patients will receive best support treatment and vaccination with racotumomab. The vaccination schedule is as follows: 5 doses (1mg/mL each), intradermally, every 2 weeks (induction period) followed by monthly vaccinations until any criteria for discontinuation are met. If disease progression occurs and further onco-specific therapy is indicated, the patient will be able to continue in the study and vaccination will not be interrupted unless criteria for vaccine discontinuation are met.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Best Support Treatment
Description: Patients will receive best support treatment for advanced NSCLC as per each institution's standards, including onco-specific therapies when disease progresses.
Study: NCT01968317

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Megestrol acetate and metformin
Description: Patients will receive metformin 500 mg by mouth third daily and megestrol acetate 160 mg by mouth daily for 3 months.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Megestrol acetate
Description: Patients will receive megestrol acetate 160 mg by mouth daily for 3 months.
Study: NCT02525978

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Video Task
Description: Subjects are asked to watch a series of six two-minute video clips. The video clips are designed to induce sad or happy emotions or no emotion (neutral) and are taken from movies, documentaries, or instructional videos. There are two videos for each emotion condition. Videos and fixation cross screens are viewed on a laptop computer. In between video clips, patients are asked to quietly look at a fixation cross for one minute, describe their emotional reaction to the video for up to one minute, then again attend to a fixation cross for one minute. A video recording of the frontal view of the participant's face will be made during task performance.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Video Task
Description: Subjects are asked to watch a series of six two-minute video clips. The video clips are designed to induce sad or happy emotions or no emotion (neutral) and are taken from movies, documentaries, or instructional videos. There are two videos for each emotion condition. Videos and fixation cross screens are viewed on a laptop computer. In between video clips, patients are asked to quietly look at a fixation cross for one minute, describe their emotional reaction to the video for up to one minute, then again attend to a fixation cross for one minute. A video recording of the frontal view of the participant's face will be made during task performance.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Imaginal Task
Description: Subjects are asked to think about happy or sad memories for 2 minutes. Subjects are asked to imagine performing neutral tasks, such as buying groceries. Subjects are then asked to think about a memory that makes them feel angry. A video recording of the frontal view of the participant's face will be made during task performance.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Imaginal Task
Description: Subjects are asked to think about happy or sad memories for 2 minutes. Subjects are asked to imagine performing neutral tasks, such as buying groceries. Subjects are then asked to think about a memory that makes them feel angry. A video recording of the frontal view of the participant's face will be made during task performance.
Study: NCT06493747

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Combined Low- and High-Frequency rTMS Intervention
Description: This intervention involves the application of rTMS using an 8-shaped coil with a frequency of 1Hz for low-frequency stimulation and 5Hz for high-frequency stimulation, in accordance with the study protocol.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Combined High- and Low-Frequency rTMS Intervention
Description: Similar to Arm A, but the sequence of low and high-frequency rTMS is reversed.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: rTMS
Description: Participants receive an individualized rTMS therapy plan based on integrated analysis of assessment data, targeting specific brain areas to enhance language function recovery post-stroke.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: rTMS + Acupuncture
Description: Participants undergo a combined treatment of rTMS as described for the rTMS Experimental Group and traditional Chinese acupuncture based on the Kaiqiao Jieyan method, targeting specific acupoints to facilitate recovery.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: rTMS
Description: Participants receive a conventional rTMS treatment as per established guidelines, serving as an active comparator to the experimental interventions.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Acupuncture
Description: Participants receive Kaiqiao Jieyan acupuncture therapy alone, without rTMS, following traditional Chinese medicine protocols for post-stroke aphasia rehabilitation.
Study: NCT01014091

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK pandemic vaccine GSK2340272A
Description: 2 intramuscular injections
Study: NCT06217679

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mixed Exercise
Description: exercise performed in randomized order

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mixed Exercise
Description: exercise performed in randomized order
Study: NCT01014091

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK pandemic vaccine GSK2340272A
Description: 2 intramuscular injections

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK pandemic vaccine GSK2340272A
Description: 2 intramuscular injections

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK pandemic vaccine GSK2340272A
Description: 2 intramuscular injections

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK pandemic vaccine GSK2340272A
Description: 2 intramuscular injections
Study: NCT06217679

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mixed Exercise
Description: exercise performed in randomized order
Study: NCT00374205

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Artemether-Lumefantrine
Description: Artemether 20 mg/Lumefantrine 120mg fixe-dose-combination tablets: 3 days twice daily weight-adjusted dosing according to manufacturer
Study: NCT05145114

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: THERAPEUTIC POSITIONS
Description: Therapeutic positioning includes placing infants in prone (prone), supine, side (lateral) decubitus, using restraint devices to provide support, reassurance and physiological stability.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: THERAPEUTIC POSITIONS
Description: Therapeutic positioning includes placing infants in prone (prone), supine, side (lateral) decubitus, using restraint devices to provide support, reassurance and physiological stability.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: THERAPEUTIC POSITIONS
Description: Therapeutic positioning includes placing infants in prone (prone), supine, side (lateral) decubitus, using restraint devices to provide support, reassurance and physiological stability.
Study: NCT04226677

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: aerobic exercise
Description: Treadmill training is include warming, cooling and training phase according to rating of perceived exertion for participants.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Video based exercise
Description: Exergame training include virtual reality games by xbox kinect.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control group
Description: first and last evaluations will be made
Study: NCT04525820

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Single high dose vitamin D
Description: Patient receives either one dose orally of 140'000 IU (7 ml) of this drug once as an intervention treatment additionally to TAU or the patient receives 7 ml of the placebo Solution (7 ml) in addition to TAU

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patient receives a single dose of a placebo solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment as usual vitamin D
Description: Both groups receive the treatment as usual after the single high dose or the placebo which will be 800 IU per day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Treatment as usual vitamin D
Description: Both groups receive the treatment as usual after the single high dose or the placebo which will be 800 IU per day
Study: NCT02657863

Intervention type: PROCEDURE
Intervention: Urine collection and blood draw
Study: NCT01403584

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AutoVPAP with addition of AutoEPAP
Description: Implementation of automated algorithm for adjustment of conventional device parameter (EPAP0.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: AutoVPAP with addition of AutoEPAP
Description: Implementation of automated algorithm for adjustment of conventional device parameter (EPAP0.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AutoVPAP with EPAP manually selected
Description: Conventionally applied Expiratory Positive Airway Pressure (EPAP)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: AutoVPAP with EPAP manually selected
Description: Conventionally applied Expiratory Positive Airway Pressure (EPAP)
Study: NCT02402751

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: acquisition of normative database with ultra high field MRI
Description: characterize non-invasively with an unprecedented resolution and sensitivity (high field MRI), anatomy as well as certain physiological, hemodynamic and metabolic function of brain, spinal cord, musculoskeletal system, and heart

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MRI
Study: NCT04743050

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fatty Acids, Unsaturated
Description: All participants from Experimental Groups will receive supplementation of different fractions of EFAs esters for six months daily. Control Group will be monitored with the same tests, but will not receive any supplementation.
Study: NCT04419259

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 334
Description: 30 subjects with rosacea will be allocated to receive monthly subcutaneous injections of 140 mg erenumab at three time points (week 0, week 4, week 8)
Study: NCT04743050

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fatty Acids, Unsaturated
Description: All participants from Experimental Groups will receive supplementation of different fractions of EFAs esters for six months daily. Control Group will be monitored with the same tests, but will not receive any supplementation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fatty Acids, Unsaturated
Description: All participants from Experimental Groups will receive supplementation of different fractions of EFAs esters for six months daily. Control Group will be monitored with the same tests, but will not receive any supplementation.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Diagnostic Tests
Description: All participants will have laboratory tests marking: CRP, fasting glucose, lipid profile, total blood count, and additional tests, which will include blood pressure measurements and measurements of body mass and composition on a specialized body composition analyzer (InBody 270). All the mentioned tests will be performed at the time of joining the research program, after 3 months (in the middle of the research program) and after 6 months (at the end of the research program).
Study: NCT03403842

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sublingual sufentanil tablet system
Description: Administration of sublingual sufentanil with a PCA

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Peridural catheter
Description: Positioning of a peridural catheter with a continuous infusion of ropivacaine 0,2% 99 ml+sufentanil 50 mcg
Study: NCT04743050

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Diagnostic Tests
Description: All participants will have laboratory tests marking: CRP, fasting glucose, lipid profile, total blood count, and additional tests, which will include blood pressure measurements and measurements of body mass and composition on a specialized body composition analyzer (InBody 270). All the mentioned tests will be performed at the time of joining the research program, after 3 months (in the middle of the research program) and after 6 months (at the end of the research program).
Study: NCT05406089

Intervention type: OTHER
Intervention: Medication history
Description: The study was retrospective and did not involve the application of interventions

Intervention type: OTHER
Intervention: Medication history
Description: The study was retrospective and did not involve the application of interventions
Study: NCT03301259

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: One-shape rotationary system
Description: OneShape (MICRO-MEGA) rotary nickel-titanium use roation movement and available in two sizes N°30 - .06 rotary files. , N°25 - .06

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: One-shape rotationary system
Description: OneShape (MICRO-MEGA) rotary nickel-titanium use roation movement and available in two sizes N°30 - .06 rotary files. , N°25 - .06
Study: NCT02522741

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Parenting STAIR
Description: Parenting-STAIR is an adaptation of a 16 session study therapy entitled Skills Training in Affective and Interpersonal Regulation/Modified Prolonged Exposure (STAIR/MPE). It generally is comprised of approximately 23 sessions and includes seven didactic interaction parenting sessions. There are threskill building in areas such as e modules within Parenting STAIR: 1) Module 1 focuses on skill building (awareness of emotional states, management of negative feelings, regulation of emotional intensity, etc.); 2) Module 2 involves the processing of memories of trauma and creating a coherent and meaningful life narrative; 3) Module 3 includes both the mother and child, and focuses on increasing maternal attunement and improving parenting skills.
Study: NCT01046942

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clopidogrel+acetylsalicylic acid
Description: loading dose clopidogrel 300mg on second postoperative day. Thereafter 75mg clopidogrel daily for 3 months Aspirin 75mg daily, started within 24 hours after surgery

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: acetylsalicylic acid
Description: aspirin 75 mg daily, started 6-24 hours after surgery
Study: NCT02789748

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Kinesthetic stimulation
Description: Activation of mechanoreceptors by vibration bursts
Study: NCT01303497

Intervention type: DRUG
Group type: OTHER
Intervention: Paclitaxel
Description: Day 1, 8 and 15 : Paclitaxel 90 mg/m², IV over 1h, during 6 cycles (1 cycle = 28 days)

Intervention type: DRUG
Group type: OTHER
Intervention: Paclitaxel
Description: Day 1, 8 and 15 : Paclitaxel 90 mg/m², IV over 1h, during 6 cycles (1 cycle = 28 days)

Intervention type: DRUG
Group type: OTHER
Intervention: Bevacizumab
Description: Bevacizumab until progression or inacceptable toxicity :~* During the cycles of chemotherapy : Day 1 and D15 : 10 mg/kg,IV~* After 6 cycles of chemotherapy : 15 mg/kg, IV
Study: NCT01402726

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: renal sympathetic modification
Description: Device: THERMOCOOL® Catheter Renal sympathetic modification with a catheter-based procedure
Study: NCT03318458

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pilates
Description: The duration of the intervention is 12 weeks, with 2 sessions per week of Pilates. Each session lasts approximately 1 hour and is structured in three parts: initial warm-up, which reviews the basic principles of the Pilates Method (centralization, concentration, movement control, breathing, movement precision and fluency) of 10 minutes duration, a 40-45 minute Pilates session and finally 10 minutes of guided relaxation. No complement was used (magic rings, fitball, elastic bands, etc.) during classes
Study: NCT01349387

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: After inclusion in the study to J0, metformin treatment will be interrupted between J1 and J30, replaced by Januvia 100 mg/day dose, then resumed at J31.
Study: NCT03403842

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PCA Morphine
Description: Administration of endovenous morphine with a PCA
Study: NCT03603327

Intervention type: DRUG
Group type: OTHER
Intervention: Direct acting anti-viral agents
Description: Standard of care for Hepatitis C treatment